Summary
A controlled trial of oral nicotinamide to prevent the onset of diabetes mellitus in high risk children was conducted in two centres. The selection criteria were age less than 16 years, islet cell antibody ≥80 IUs, and first phase insulin release < 5th percentile. All of eight untreated control subjects have developed diabetes, whereas only 1 of 14 treated children has diabetes to date. This data suggests that nicotinamide has an effect in preventing Type 1 (insulin-dependent) diabetes and that randomized controlled studies are now indicated.
Article PDF
Similar content being viewed by others
References
Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet II: 1279–1283
Tarn AC, Thomas JM, Dean BM, Ingram D, Schwarz G, Bottazzo GF, Gale EM (1988) Predicting insulin-dependent diabetes. Lancet I: 845–850
Srikanta S, Ganda OP, Soeldner JS, Eisenbarth GS (1985) First-degree relatives of patients with type 1 diabetes: islet cell antibodies and abnormal insulin secretion. N Engl J Med 313: 461–464
Chase HP, Voss MA, Butler-Simon N, Hoops S, O'Brien D, Dobersen MJ (1987) Diagnosis of pre-type 1 diabetes. J Pediatr 111: 807–812
Srikanta S, Ganda OP, Gleason RE, Jackson RA, Soeldner JS, Eisenbarth GS (1984) Pre-type 1 diabetes linear loss of β cell response to intravenous glucose. Diabetes 33: 717
Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S (1982) Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. Diabetes 31: 749–753
Elliott RB, Bibby NJ, Reddy S (1990) Dietary prevention and enhancement of diabetes in the N.O.D. mouse. In Shafir E, Vardy P (eds) Proceedings: Immunology of Diabetes 19th International Workshop. Jerusalem, p 34 (Abstract)
Hermitte L, Vialettes B, Atlef N, Payan MJ, Doll N, Scheimann A, Vague Ph (1989) High dose nicotinamide fails to prevent diabetes in BB rats. Autoimmunity 5: 79–86
Vague P, Vialettes B, Lassman-Vague V, Vallo JJ (1987) Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet I: 619–620
Vague P, Picq R, Bernal M, Lassman-Vague V, Vialettes B (1989) Effect of nicotinamide treatment on the residual insulin secretion in Type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 316–321
Mendola G, Casamitjana R, Gomis R (1990) Effect of nicotinamide therapy upon Beta-cell function in newly diagnosed Type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 160–162
Chase HP, Butler-Simon N, Garg S, McDuffie M, Hoops SL, O'Brien D (1990) A trial of nicotinamide in newly diagnosed patients with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33: 444–446
Chase HP, Garg SK, Klingensmith G (1990) Prediction and possible modification of the course of pre-Type 1 diabetes. Diabetes 39: 103 a (Abstract)
Pilcher CC, Elliott RB (1990) A sensitive and reproducible method for the assay of human islet cell antibodies. J Immunol M 129: 111–117
Ziegler AG, Ziegler R, Vardi P, Jackson RA, Soeldner JS, Eisenbarth GS (1989) Life-table analysis of progression to diabetes of anti-insulin autoantibody-positive relatives of individuals with Type 1 diabetes. Diabetes 38: 1320–1325
Cox DR, Oaken D (1984) Analysis of survival data 1st edn. Chapman and Hall, London, pp 48–56
LeDoux SP, Hall CR, Forbes PM, Patton NJ, Wilson GL (1988) Mechanisms of nicotinamide and thymidine protection from alloxan and streptozotocin toxicity. Diabetes 37: 1015–1019
Uchigata Y, Yamamoto H, Nagai H, Okamoto H (1983) Effect of poly(ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis. Diabetes 32: 316–318
Kolb H, Burkart V, Appels B, Hannenberg H, Kantwerk-Funke G, Kiesel U, Funda J, Schraermeyer U, Kolb-Bachofen V (1990) Essential contribution of macrophages to islet cell destruction in vivo and in vitro. J Autoimmun 3: 1–4
Yamada K, Miyajima E, Nonaka K (1990) Inhibition of cytokine-induced MHC class II but not class I molecule expression on mouse islet cells by niacinamide and 3-aminobenzamide. Diabetes 39: 1125–1130
Yamagami T, Miwa A, Takasawa S, Yamamoto H, Okamoto H (1985) Induction of rat pancreatic beta-cell tumors by the combined administration of streptozotocin or alloxan and poly (adenosine diphosphate ribose) synthetase inhibitors. Cancer Res 45: 1845–1849
Smith CP, Williams AJK, Thomas JM, Archibald R, Algar VD, Bottazzo GF, Gale EAM, Savage MO (1988) The pattern of basal and stimulated insulin responses to intravenous glucose in first degree relatives of Type 1 (insulin-dependent) diabetic children and unrelated adults aged 5–50 years. Diabetologia 31: 430–434
Herskowitz RD, Jackson RA, Soeldner JS, Eisenbarth GS (1989) Pilot trial to prevent type 1 diabetes: progression to overt IDDM despite oral nicotinamide. J Autoimmunity 2: 733
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elliott, R.B., Chase, H.P. Prevention or delay of Type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34, 362–365 (1991). https://doi.org/10.1007/BF00405010
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00405010